24 February 2026
24 February 2026
Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.
The aim of the pathway is to remove red tape for bespoke therapies designed for patients with rare diseases.
This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the impacts of key patent expiries within its portfolio.
Sanofi and Bavarian Nordics are amongst the recipients of contracts that will run for around eight years to help bring new products to market.
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
The submission includes data indicating a meaningful survival benefit for infantile-onset NPC patients treated with adrabetadex.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
